Annual SG&A
$18.33 M
-$2.21 M-10.77%
31 December 2023
Summary:
Cidara Therapeutics annual selling, general & administrative expenses is currently $18.33 million, with the most recent change of -$2.21 million (-10.77%) on 31 December 2023. During the last 3 years, it has risen by +$2.43 million (+15.31%). CDTX annual SG&A is now -10.77% below its all-time high of $20.55 million, reached on 31 December 2022.CDTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$4.96 M
+$219.00 K+4.61%
30 September 2024
Summary:
Cidara Therapeutics quarterly selling, general & administrative expenses is currently $4.96 million, with the most recent change of +$219.00 thousand (+4.61%) on 30 September 2024. Over the past year, it has increased by +$1.67 million (+50.50%). CDTX quarterly SG&A is now -39.45% below its all-time high of $8.20 million, reached on 31 December 2023.CDTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.00 B
-$134.66 M-7.24%
30 September 2024
Summary:
Cidara Therapeutics TTM selling, general & administrative expenses is currently -$2.00 billion, with the most recent change of -$134.66 million (-7.24%) on 30 September 2024. Over the past year, it has dropped by -$2.01 billion (-12246.76%). CDTX TTM SG&A is now -14896.28% below its all-time high of $23.91 million, reached on 30 September 2024.CDTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CDTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.8% | +50.5% | -10000.0% |
| 3 y3 years | +15.3% | +7.8% | -10000.0% |
| 5 y5 years | +29.6% | +8.6% | -10000.0% |
CDTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -10.8% | +15.3% | -39.5% | +56.1% | -43.5% | at low |
| 5 y | 5 years | -10.8% | +29.6% | -39.5% | +56.1% | -110.3% | at low |
| alltime | all time | -10.8% | +6640.1% | -39.5% | +1666.9% | <-9999.0% | at low |
Cidara Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.96 M(+4.6%) | $23.91 M(+7.5%) |
| June 2024 | - | $4.75 M(-20.9%) | $22.24 M(+7.6%) |
| Mar 2024 | - | $6.00 M(-26.9%) | $20.68 M(+8.1%) |
| Dec 2023 | $18.33 M(-10.8%) | $8.20 M(+148.6%) | $19.14 M(+16.5%) |
| Sept 2023 | - | $3.30 M(+3.7%) | $16.43 M(-13.1%) |
| June 2023 | - | $3.18 M(-28.6%) | $18.91 M(-4.5%) |
| Mar 2023 | - | $4.46 M(-18.8%) | $19.80 M(-3.6%) |
| Dec 2022 | $20.55 M(+9.6%) | $5.49 M(-5.1%) | $20.55 M(+2.5%) |
| Sept 2022 | - | $5.78 M(+41.9%) | $20.04 M(+6.2%) |
| June 2022 | - | $4.07 M(-21.7%) | $18.87 M(-1.5%) |
| Mar 2022 | - | $5.20 M(+4.5%) | $19.16 M(+2.3%) |
| Dec 2021 | $18.74 M(+17.9%) | $4.98 M(+8.1%) | $18.74 M(+4.7%) |
| Sept 2021 | - | $4.61 M(+5.4%) | $17.91 M(+5.4%) |
| June 2021 | - | $4.37 M(-8.6%) | $16.99 M(+2.4%) |
| Mar 2021 | - | $4.78 M(+15.3%) | $16.59 M(+4.3%) |
| Dec 2020 | $15.90 M(-2.1%) | $4.15 M(+12.5%) | $15.90 M(-1.6%) |
| Sept 2020 | - | $3.69 M(-7.1%) | $16.16 M(-5.2%) |
| June 2020 | - | $3.97 M(-3.1%) | $17.04 M(+2.7%) |
| Mar 2020 | - | $4.09 M(-7.0%) | $16.60 M(+2.2%) |
| Dec 2019 | $16.24 M | $4.41 M(-3.7%) | $16.24 M(+5.5%) |
| Sept 2019 | - | $4.57 M(+29.7%) | $15.38 M(+7.9%) |
| June 2019 | - | $3.52 M(-5.6%) | $14.26 M(-0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $3.73 M(+5.2%) | $14.27 M(+0.9%) |
| Dec 2018 | $14.14 M(+9.7%) | $3.55 M(+3.0%) | $14.14 M(+2.3%) |
| Sept 2018 | - | $3.45 M(-2.4%) | $13.82 M(+2.7%) |
| June 2018 | - | $3.53 M(-2.2%) | $13.46 M(+0.8%) |
| Mar 2018 | - | $3.61 M(+11.8%) | $13.35 M(+3.5%) |
| Dec 2017 | $12.90 M(+1.3%) | $3.23 M(+4.5%) | $12.90 M(+1.5%) |
| Sept 2017 | - | $3.09 M(-9.8%) | $12.71 M(-3.9%) |
| June 2017 | - | $3.42 M(+8.5%) | $13.23 M(+0.3%) |
| Mar 2017 | - | $3.15 M(+3.7%) | $13.20 M(+3.6%) |
| Dec 2016 | $12.74 M(+44.1%) | $3.04 M(-15.6%) | $12.74 M(+5.6%) |
| Sept 2016 | - | $3.61 M(+6.4%) | $12.06 M(+10.7%) |
| June 2016 | - | $3.39 M(+25.8%) | $10.89 M(+11.9%) |
| Mar 2016 | - | $2.70 M(+14.0%) | $9.74 M(+10.2%) |
| Dec 2015 | $8.84 M(+167.3%) | $2.36 M(-3.2%) | $8.84 M(+15.5%) |
| Sept 2015 | - | $2.44 M(+9.2%) | $7.65 M(+17.0%) |
| June 2015 | - | $2.24 M(+24.4%) | $6.54 M(+35.5%) |
| Mar 2015 | - | $1.80 M(+52.9%) | $4.82 M(+45.9%) |
| Dec 2014 | $3.31 M(+1115.4%) | $1.18 M(-11.5%) | $3.31 M(+55.1%) |
| Sept 2014 | - | $1.33 M(+154.4%) | $2.13 M(+165.4%) |
| June 2014 | - | $522.00 K(+85.8%) | $803.00 K(+185.8%) |
| Mar 2014 | - | $281.00 K | $281.00 K |
| Dec 2013 | $272.00 K | - | - |
FAQ
- What is Cidara Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Cidara Therapeutics?
- What is Cidara Therapeutics annual SG&A year-on-year change?
- What is Cidara Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Cidara Therapeutics?
- What is Cidara Therapeutics quarterly SG&A year-on-year change?
- What is Cidara Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Cidara Therapeutics?
- What is Cidara Therapeutics TTM SG&A year-on-year change?
What is Cidara Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of CDTX is $18.33 M
What is the all time high annual SG&A for Cidara Therapeutics?
Cidara Therapeutics all-time high annual selling, general & administrative expenses is $20.55 M
What is Cidara Therapeutics annual SG&A year-on-year change?
Over the past year, CDTX annual selling, general & administrative expenses has changed by -$2.21 M (-10.77%)
What is Cidara Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of CDTX is $4.96 M
What is the all time high quarterly SG&A for Cidara Therapeutics?
Cidara Therapeutics all-time high quarterly selling, general & administrative expenses is $8.20 M
What is Cidara Therapeutics quarterly SG&A year-on-year change?
Over the past year, CDTX quarterly selling, general & administrative expenses has changed by +$1.67 M (+50.50%)
What is Cidara Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of CDTX is -$2.00 B
What is the all time high TTM SG&A for Cidara Therapeutics?
Cidara Therapeutics all-time high TTM selling, general & administrative expenses is $23.91 M
What is Cidara Therapeutics TTM SG&A year-on-year change?
Over the past year, CDTX TTM selling, general & administrative expenses has changed by -$2.01 B (-12246.76%)